Search results
Results from the WOW.Com Content Network
The authors came to the conclusion that no further trials of hydroxychloroquine or chloroquine for treatment of COVID-19 should be carried out. [58] On 26 April 2021, in its amended clinical management protocol for COVID-19, the Indian Ministry of Health lists hydroxychloroquine for use in patients during the early course of the disease. [23]
This registry based, multi-center, multi-country data provide provisional support for the use of ECMO for COVID-19 associated acute hypoxemic respiratory failure. Given that this is a complex technology that can be resource intense, guidelines exist for the use of ECMO during the COVID-19 pandemic. [85] [86] [87]
From the early outbreak of the COVID-19 pandemic, rumors and speculation arose about the possible lab origins of SARS-CoV-2, the causative agent of the COVID-19 disease. . Different versions of the lab origin hypothesis present different scenarios in which a bat-borne progenitor of SARS-COV-2 may have spilled over to humans, including a laboratory-acquired infection of a natural or engineered vi
The Great Barrington Declaration is an open letter published in October 2020 in response to the COVID-19 pandemic and lockdowns. [1] [2] It claimed harmful COVID-19 lockdowns could be avoided via the fringe notion of "focused protection", by which those most at risk of dying from an infection could purportedly be kept safe while society otherwise took no steps to prevent infection.
The Randomised Evaluation of COVID-19 Therapy (RECOVERY Trial) [1] is a large-enrollment clinical trial of possible treatments for people in the United Kingdom admitted to hospital with severe COVID-19 infection. [2] [3] [4] The trial was later expanded to Indonesia, Nepal and Vietnam. [5]
From the early outbreak of the COVID-19 pandemic, rumors and speculation arose about the possible lab origins of SARS-CoV-2, the causative agent of the COVID-19 disease.. Different versions of the lab origin hypothesis present different scenarios in which a bat-borne progenitor of SARS-CoV-2 may have spilled over to humans, including a laboratory-acquired infection of a natural or engineered vir
[2] [16] Following a study published by The Lancet on safety concerns with hydroxychloroquine, the WHO suspended use of it from the Solidarity trial in May 2020, [197] [198] reinstated it after the research was retracted, [199] then abandoned further use of the drug for COVID-19 treatment when analysis showed in June that it provided no benefit ...
The FDA later clarified that it has not approved any therapeutics or drugs to treat COVID-19, but that studies were underway to see if chloroquine could be effective in treatment of COVID-19. [146] [147] Following Trump's claim, panic buying of chloroquine was reported from many countries in Africa, Latin America and South Asia. Health ...